Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.

@article{Fujiyama1986ClinicalEO,
  title={Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.},
  author={Shigetoshi Fujiyama and Tetsuo Morishita and Katsuro Sagara and Tsutomu Sato and Kentaro Motohara and Ichiro Matsuda},
  journal={Hepato-gastroenterology},
  year={1986},
  volume={33 5},
  pages={201-5}
}
The clinical usefulness of plasma abnormal prothrombin, defined as a protein induced by vitamin K absence or antagonist-II: PIVKA-II, as a tumor marker for hepatocellular carcinoma (HCC), was evaluated. Plasma PIVKA-II concentration was determined by an enzyme-linked immunosorbent assay (ELISA) using a monoclonal antibody specific for PIVKA-II. Forty-one (65%) out of 63 patients with HCC had an abnormal PIVKA-II level above 0.13 arbitrary units (AU)/ml; the level was above 0.3 AU/ml in 33… CONTINUE READING

Similar Papers

Loading similar papers…